Cynvenio Announces New PD-L1 Test For Tumor Cells In Blood

LOS ANGELES--(BUSINESS WIRE)--Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for cancer patients, announced that it has developed, validated, and fully implemented a PD-L1 (Programmed Death-Ligand 1) assay for circulating tumor cells (CTCs) obtained via its LiquidBiopsy® technology for several tumor subtypes.

Help employers find you! Check out all the jobs and post your resume.